Form 8-K - Current report:
SEC Accession No. 0000950170-23-072612
Filing Date
2023-12-22
Accepted
2023-12-22 16:00:10
Documents
13
Period of Report
2023-12-18
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K meip-20231218.htm   iXBRL 8-K 38173
2 EX-3.1 meip-ex3_1.htm EX-3.1 112661
  Complete submission text file 0000950170-23-072612.txt   291322

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT meip-20231218_lab.xml EX-101.LAB 13343
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT meip-20231218_pre.xml EX-101.PRE 9842
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT meip-20231218.xsd EX-101.SCH 2472
7 EXTRACTED XBRL INSTANCE DOCUMENT meip-20231218_htm.xml XML 4705
Mailing Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130
Business Address 11455 EL CAMINO REAL SUITE 250 SAN DIEGO CA 92130 858-369-7100
MEI Pharma, Inc. (Filer) CIK: 0001262104 (see all company filings)

EIN.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-41827 | Film No.: 231509678
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)